Last update March 9, 2021

C17 H14 O4 S

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Non-steroidal anti-inflammatory drug (NSAID) that functions as a selective inhibitor of the cyclooxygenase-2 (COX-2) enzyme.
It was administered orally for the treatment of osteoarthritis, rheumatoid arthritis, acute pain, dysmenorrhea, and migraine until its withdrawal from the market.
It is still available for topical cutaneous application.

Excreted in negligible amounts through breastmilk (Gardiner 2005).

It was withdrawn from the global market in 2004 due to a high risk of cardiovascular toicity (Myocardial infarction, ictus) in people that used it frequently.

Use of preparations for topical application would be compatible with breastfeeding.

Alternatives

  • Celecoxib ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Ibuprofen ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

C17 H14 O4 S is Rofecoxib in Molecular formula.

Is written in other languages:

Tradenames

Main tradenames from several countries containing C17 H14 O4 S in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 93 %
Molecular weight 314 daltons
Protein Binding 87 %
VD 1.3 l/Kg
pKa 14.84 -
Tmax 2 - 4 hours
17 hours
M/P ratio 0.25 (0.16 - 0.32) -
Theoretical Dose 0.008 mg/Kg/d
Relative Dose 2.1 (1.8 - 3.2) %

References

  1. Gardiner SJ, Begg EJ, Zhang M, Hughes RC. Transfer of rofecoxib into human milk. Eur J Clin Pharmacol. 2005 Abstract

Total visits

640

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM